France· FR:63892609
TRIUMEQ 5 mg/60 mg/30 mg, comprimé dispersible
A medicinal product containing lamivudine + dolutégravir sodique + sulfate d'abacavir, registered in France by VIIV HEALTHCARE (PAYS-BAS), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- LAMIVUDINE + DOLUTÉGRAVIR SODIQUE + SULFATE D'ABACAVIR
- Manufacturer
- VIIV HEALTHCARE (PAYS-BAS)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009302665331 flacon polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 90 comprimés + 1 godet doseurEUR 290.64
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lamivudine + dolutégravir sodique + sulfate d'abacavir in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandTriumeqViiV Healthcare BV
- CzechiaTRIUMEQViiV Healthcare BV, Amersfoort
- SpainTRIUMEQ 5 MG/60 MG/30 MG COMPRIMIDOS DISPERSABLESViiv Healthcare B.V.
- SwitzerlandTriumeq, FilmtablettenViiV Healthcare GmbH
- United KingdomTriumeq 50mg/600mg/300mg tabletsViiV Healthcare UK Ltd
- IrelandTriumeq 5 mg/60 mg/30 mg dispersible tabletsViiV Healthcare BV
- IcelandTriumeqViiV Healthcare BV
- NetherlandsTriumeq 5 mg/ 60 mg/ 30 mg dispergeerbare tablettenViiV Healthcare B.V.
Authorised across Europe · EMA
The same active substance is authorised in 5 EEA countries. Names it is sold under:
- Iceland · Triumeq
- Liechtenstein · Triumeq
- Malta · Dolutegravir/Abacavir/Lamivudine Pharos
- Norway · Triumeq
- Portugal · Dolutegravir/Abacavir/Lamivudine Pharos
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3455207a-857c-4812-b5f3-6f587f081ebb GET /v1/drugs/3455207a-857c-4812-b5f3-6f587f081ebb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "63892609",
"date_amm": "2023-02-20",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/14/940",
"substance": "LAMIVUDINE + DOLUTÉGRAVIR SODIQUE + SULFATE D'ABACAVIR",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé dispersible",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about lamivudine + dolutégravir sodique + sulfate d'abacavir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.